RARA CRAFT DATABASE for FDA Medical Devices
510(k)K171657

FDA DEVICE FACTS

ShurFit 2C Lumbar Interbody Fusion System

Precision Spine, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEAugust 11, 2017PRODUCT CODEMAX

Indications for use

The ShurFit 2C Interbody Fusion Devices (LLIF and TLIF) are indicated for intervertebral body fusion of the spine in skeletally mature patients. The device is designed to be used with autograft to facilitate fusion. One device is used per intervertebral space for the LLIF and TLIF. The ShurFit 2C Interbody Fusion Devices (LLIF and TLIF) are intended for use at either one level or two contiguous levels in the lumbar spine, for L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade I spondylolisthesis. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. The lumbar device is to be used with supplemental fixation and autogenous autograft. Patients should have at least six months of non-operative treatment prior to treatment with a lumbar intervertebral fusion device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 29, 2026